Jefferies Financial Group Inc

Jefferies Financial Group has launched and completed several fixed income offerings dated August 13, 2026, raising longer term funding through the bond market. The issuances include fixed coupon senior unsecured notes with maturities in 2029, 2031, 2036, 2046, and 2051, all issued at 100% of principal value and featuring callable structures under a global medium term note program. Specific tranches include 5.70% notes due August 17, 2031 with a principal amount of US$5.937 million and a 0.5% discount per security, 6.50% notes due August 17, 2036 with a principal amount of US$5.936 million and a 1% discount per security, and 7.00% notes due August 17, 2046 with a principal amount of US$5.258 million and a 2% discount per security. The company also announced 7.00% notes due August 31, 2051 and 5% notes due February 28, 2029, both senior unsecured and callable under the same global MTN framework. Jefferies Financial Group shares have slipped 3.48% over the past 30 days and 13.11% year to date, despite a 74.25% three-year total shareholder return and a 93.26% five-year total shareholder return, as investors weigh the new bond issuance alongside ongoing legal investigations and updated research coverage.

Jefferies Financial Group is under investigation by law firm Bragar Eagel & Squire, P.C. over its exposure to the collapse of First Brands, introducing legal and regulatory uncertainty. The company has also announced a series of new senior unsecured callable notes with fixed coupons ranging from 5.70% to 7.00% and maturities between 2031 and 2056, following earlier completed issuances totaling about US$7.34 million. The investigation and the expanded bond funding are now key factors shaping the investment narrative for Jefferies, alongside its core investment banking and capital markets performance.

Kirby McInerney LLP is investigating Jefferies Financial Group, Inc. for potential violations of federal securities laws. The investigation follows Jefferies' June 25, 2026 quarterly report, which revealed weaker asset-management fees and investment returns partly tied to its Point Bonita Capital unit. The SEC is reportedly probing claims that Jefferies misled investors about its exposure to First Brands Group, a bankrupt auto-parts supplier, through Point Bonita, where funds were owed roughly $715 million from companies that bought First Brands' parts. Jefferies later disclosed a $30 million loss related to the collapse, and its share price fell $5.30, or about 9%, from $57.94 on June 24 to close at $52.64 on June 25, 2026. No lawsuit has been filed, and the investigation is ongoing.

Jefferies Financial Group is reviewing its remaining exposure to commodities trader Radiant World after questions emerged about documents used to support some of the company's trade finance transactions, Bloomberg News reported Sunday. The firm's exposure has been reduced to less than $300 million from a much higher level, and the review comes as Jefferies is still working to recover from losses tied to auto supplier First Brands and other troubled investments. Payments from Radiant World had slowed in recent months as Jefferies' Point Bonita Capital fund wound down, and an internal review reportedly uncovered inconsistencies in paperwork supporting some financing transactions. The review follows reports that major commodities firms, including Vitol and Cargill, have stopped trading with Radiant World over concerns about the authenticity of invoices and other documents presented to banks, though Radiant World has denied any wrongdoing. The latest episode revives memories of Point Bonita's losses tied to First Brands, where investors had been told the fund's largest exposures were to blue-chip companies such as Walmart and AutoZone, but the investments were actually receivables purchased from First Brands that were backed by invoices from those companies, leading to significant losses when First Brands collapsed.

Eaton Partners, a wholly-owned subsidiary of Stifel Financial Corp., has appointed Mickey Brunton as Managing Director and Co-Head of GP-led Secondaries within its Private Capital Advisory group. Brunton joins from Connaught LLC, where he was Head of Secondaries and originated approximately $500 million in secondary transactions. He previously advised on more than $4 billion in secondary transactions at Jefferies. Alongside Brunton, three other former Connaught professionals—Stephen Sellman, Matt Reynolds, and Darian Brill—also join Eaton Partners. The firm has raised more than $140 billion across over 190 alternative investment funds and offerings since its founding in 1983.

Bragar Eagel & Squire, P.C. is investigating potential claims against Jefferies Financial Group Inc. on behalf of Jefferies stockholders. The investigation concerns whether Jefferies violated federal securities laws or engaged in other unlawful business practices. The firm cites a series of events beginning with a Wall Street Journal report on September 29, 2025, about auto supplier First Brands filing for bankruptcy amid accounting questions, followed by reports that Jefferies' Point Bonita Capital unit was owed around $715 million from companies that bought First Brands' parts. Subsequent news included a U.S. Department of Justice inquiry into First Brands' collapse, an SEC investigation into Jefferies' relationship with First Brands, a $30 million loss tied to the collapse, and a June 24, 2026 earnings miss where Jefferies disclosed lower management fees driven by Point Bonita and its strategic affiliates. Stockholders who purchased or acquired Jefferies shares and suffered a loss are encouraged to contact the firm's partners, Brandon Walker or Melissa Fortunato, at investigations@bespc.com or (212) 355-4648.

Pomerantz LLP is investigating claims on behalf of investors of Jefferies Financial Group Inc. regarding potential securities fraud or unlawful business practices. The investigation follows reports that Jefferies' asset-management unit, Point Bonita Capital, was owed around $715 million from companies that bought parts from First Brands Group, which filed for bankruptcy amid accounting questions. Jefferies' stock fell 7.88% on October 8, 2025, after The Wall Street Journal reported the exposure, and dropped another 2.63% the next day when Reuters disclosed a U.S. Department of Justice inquiry into First Brands. Further declines occurred after The Financial Times reported an SEC investigation into Jefferies' disclosures to Point Bonita investors and a $30 million loss tied to First Brands, and again after Jefferies' June 2026 earnings missed estimates, partly due to lower fees from Point Bonita.

Jefferies Financial Group is under investigation by the U.S. Department of Justice and the Securities and Exchange Commission over its exposure to bankrupt auto supplier First Brands. Multiple law firms are also examining potential securities law violations and disclosure issues, focusing on whether Jefferies accurately described its exposure through Point Bonita Capital and how a reported $30 million loss was communicated. The stock has fallen 11.7% over the past 30 days and 19.5% year to date, closing at $51.1. Potential outcomes include fines, litigation settlements, and tighter oversight, though Jefferies has continued to access bond markets with recent senior unsecured note offerings in euros and U.S. dollars. The timeline for resolution is expected to be extended, and the stock may remain sensitive to legal headlines.

Analysts have trimmed their fair value estimate for AstraZeneca slightly from £165.09 to £164.85, reflecting a measured shift in valuation assumptions rather than a sharp rethink. The adjustment comes alongside commentary on how regulators, pricing decisions, and recent advisory outcomes could shape the company's growth options, execution risk, and pipeline assumptions. Key inputs include an unchanged long-term annual dollar revenue growth assumption of 6.38%, a projected net profit margin updated from 22.57% to 22.96%, and a future P/E multiple reduced from 25.83x to 25.09x, with the discount rate effectively unchanged at 7.38%. Recent developments include FDA approval of TRUQAP as the first targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer, a planned US$50 billion investment to expand U.S. manufacturing and R&D, and advancement of the oral GLP-1 agonist elecoglipron into a broad phase 3 program in obesity and Type 2 diabetes. Bullish analysts from Citi, Morgan Stanley, and Guggenheim raised price targets, while Jefferies flagged execution risk after an ODAC vote against the SERENA 6 program.

UBS downgraded Jefferies Financial Group to neutral from buy, citing limited upside after a 50% quarterly stock rally. The brokerage raised its 12-month price target to $67 from $59 and lifted its second-quarter earnings-per-share estimate by 95% to $1.45, more than 40% above consensus. UBS noted that Jefferies' heavy reliance on sponsor-driven deal flow, at roughly 60% of activity versus 45% to 50% for peers, leaves it more exposed to a slow recovery in that segment. The firm also said near-term catalysts from Sumitomo Mitsui Banking Corp's open-market share purchases appear largely done, while longer-term partnership benefits will take time to materialize.